Literature DB >> 33530433

The Protective Role of Sestrin2 in Atherosclerotic and Cardiac Diseases.

Yoshimi Kishimoto1, Kazuo Kondo2, Yukihiko Momiyama3.   

Abstract

Atherosclerotic disease, such as coronary artery disease (CAD), is known to be a chronic inflammatory disease, as well as an age-related disease. Excessive oxidative stress produced by reactive oxygen species (ROS) contributes to the pathogenesis of atherosclerosis. Sestrin2 is an anti-oxidant protein that is induced by various stresses such as hypoxia, DNA damage, and oxidative stress. Sestrin2 is also suggested to be associated with aging. Sestrin2 is expressed and secreted mainly by macrophages, endothelial cells, and cardiomyocytes. Sestrin2 plays an important role in suppressing the production and accumulation of ROS, thus protecting cells from oxidative damage. Since sestrin2 is reported to have anti-oxidant and anti-inflammatory properties, it may play a protective role against the progression of atherosclerosis and may be a potential therapeutic target for the amelioration of atherosclerosis. Regarding the association between blood sestrin2 levels and atherosclerotic disease, the blood sestrin2 levels in patients with CAD or carotid atherosclerosis were reported to be high. High blood sestrin2 levels in patients with such atherosclerotic disease may reflect a compensatory response to increased oxidative stress and may help protect against the progression of atherosclerosis. This review describes the protective role of sestrin2 against the progression of atherosclerotic and cardiac diseases.

Entities:  

Keywords:  atherosclerosis; carotid plaque; coronary artery disease; inflammation; oxidative stress; sestrin2

Mesh:

Substances:

Year:  2021        PMID: 33530433      PMCID: PMC7865804          DOI: 10.3390/ijms22031200

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  56 in total

Review 1.  Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS.

Authors:  Kathy K Griendling; Garret A FitzGerald
Journal:  Circulation       Date:  2003-10-21       Impact factor: 29.690

2.  Association of serum Sestrin2 level with metabolic risk factors in newly diagnosed drug-naïve type 2 diabetes.

Authors:  Hye Soo Chung; Hwan-Jin Hwang; Soon Young Hwang; Nam Hoon Kim; Ji A Seo; Sin Gon Kim; Nan Hee Kim; Sei Hyun Baik; Kyung Mook Choi; Hye Jin Yoo
Journal:  Diabetes Res Clin Pract       Date:  2018-08-10       Impact factor: 5.602

3.  Increased plasma sestrin2 concentrations in patients with chronic heart failure and predicted the occurrence of major adverse cardiac events: A 36-month follow-up cohort study.

Authors:  Haixiong Wang; Na Li; Xin Shao; Jun Li; Liping Guo; Xingyan Yu; Yuehui Sun; Jinlin Hao; Huaimin Niu; Jie Xiang; Xiaofang Li; Xuebin Han
Journal:  Clin Chim Acta       Date:  2019-05-03       Impact factor: 3.786

4.  Sestrin2 protects the myocardium against radiation-induced damage.

Authors:  Yue-Can Zeng; Feng Chi; Rui Xing; Jing Zeng; Song Gao; Jia-Jia Chen; Hong-Mei Wang; Qiong-Yu Duan; Yu-Nan Sun; Nan Niu; Mei-Yue Tang; Rong Wu
Journal:  Radiat Environ Biophys       Date:  2016-03-15       Impact factor: 1.925

5.  Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage.

Authors:  Soo Han Bae; Su Haeng Sung; Sue Young Oh; Jung Mi Lim; Se Kyoung Lee; Young Nyun Park; Hye Eun Lee; Dongmin Kang; Sue Goo Rhee
Journal:  Cell Metab       Date:  2012-12-27       Impact factor: 27.287

6.  Sestrin2 decreases renal oxidative stress, lowers blood pressure, and mediates dopamine D2 receptor-induced inhibition of reactive oxygen species production.

Authors:  Yu Yang; Santiago Cuevas; Sufei Yang; Van Anthony Villar; Crisanto Escano; Laureano Asico; Peiying Yu; Xiaoliang Jiang; Edward J Weinman; Ines Armando; Pedro A Jose
Journal:  Hypertension       Date:  2014-07-14       Impact factor: 10.190

Review 7.  CVD and Oxidative Stress.

Authors:  Karla Cervantes Gracia; Daniel Llanas-Cornejo; Holger Husi
Journal:  J Clin Med       Date:  2017-02-20       Impact factor: 4.241

8.  Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3.

Authors:  Jun Hee Lee; Andrei V Budanov; Saswata Talukdar; Eek Joong Park; Hae Li Park; Hwan-Woo Park; Gautam Bandyopadhyay; Ning Li; Mariam Aghajan; Insook Jang; Amber M Wolfe; Guy A Perkins; Mark H Ellisman; Ethan Bier; Miriam Scadeng; Marc Foretz; Benoit Viollet; Jerrold Olefsky; Michael Karin
Journal:  Cell Metab       Date:  2012-09-05       Impact factor: 27.287

9.  p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling.

Authors:  Andrei V Budanov; Michael Karin
Journal:  Cell       Date:  2008-08-08       Impact factor: 41.582

10.  Association between Plasma Sestrin2 Levels and the Presence and Severity of Coronary Artery Disease.

Authors:  Yoshimi Kishimoto; Masayuki Aoyama; Emi Saita; Yukinori Ikegami; Reiko Ohmori; Kazuo Kondo; Yukihiko Momiyama
Journal:  Dis Markers       Date:  2020-06-30       Impact factor: 3.434

View more
  4 in total

1.  ER stress induces myocardial dysfunction and cardiac autophagy in Sestrin2 knockout mice.

Authors:  Jie Zhang; Linlin Yao; Shaohua Li; Misbahul Ferdous; Peng Zhao
Journal:  Am J Transl Res       Date:  2022-08-15       Impact factor: 3.940

Review 2.  Oxidative Stress-Induced Protein of SESTRIN2 in Cardioprotection Effect.

Authors:  Huang Rongjin; Chen Feng; Ke Jun; Lin Shirong
Journal:  Dis Markers       Date:  2022-07-29       Impact factor: 3.464

3.  Serum Sestrin2 Was Lower in Septic Shock Patients with Cardiomyopathy.

Authors:  Rongjin Huang; Feng Chen; Aiying Zeng; Jun Ke; Shirong Lin
Journal:  Dis Markers       Date:  2022-09-01       Impact factor: 3.464

4.  Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease.

Authors:  Yuting Ma; Guangdong Zhang; Zenggguang Kuang; Qian Xu; Tongtong Ye; Xue Li; Na Qu; Fang Han; Chengxia Kan; Xiaodong Sun
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.